MoonLake shares surge 10% on Phase 2 axSpA trial success
81% of patients achieved primary endpoint in sonelokimab study, demonstrating disease modification potential
MoonLake Immunotherapeutics shares surged more than 10% in pre-market trading Monday after the Swiss biotech reported positive topline results from its Phase 2 S-OLARIS trial evaluating sonelokimab in patients with axial spondyloarthritis, marking a significant milestone for the $1.3 billion company.
The study demonstrated that 81% of patients treated with sonelokimab achieved an ASAS40 response at Week 12, representing at least 40% improvement across key disease domains. This result exceeds benchmarks typically seen with currently approved therapies for the chronic inflammatory condition, which causes pain and stiffness primarily in the spine and sacroiliac joints.
More than 80% of patients showed clinically important improvement in ASDAS-CRP scores, while imaging data revealed significant reductions in inflammation. The trial enrolled 26 patients with both radiographic and non-radiographic forms of the disease, providing evidence across the axSpA spectrum.
Perhaps most significant for long-term competitive positioning, PET imaging demonstrated reduced osteoblast activity in affected joints, suggesting sonelokimab may offer disease-modifying potential rather than merely symptom relief. The safety profile remained consistent with previous studies, with no new signals identified.
"The magnitude of ASAS40 response at 81% is exceptional and positions sonelokimab as a potential best-in-class therapy in the axSpA market," noted analysts at FierceBiotech, which characterized the win as kicking off a pivotal year for the interleukin-17 nanobody approach.
The company, which closed 2025 with $394 million in cash and has access to a $500 million debt facility, has sufficient runway into the second half of 2027. An additional $75 million equity raise earlier this year bolstered the balance sheet as the company advances its pipeline.
MoonLake plans to discuss the results and broader pipeline strategy during an investor webcast scheduled for Monday. The company targets a Biologics License Application submission for hidradenitis suppurativa in the second half of 2026, while the FDA granted Fast Track designation for palindromic rheumatism in February.
Analysts at major firms maintain a predominantly bullish outlook on the stock, with 10 Buy ratings compared to 4 Hold and 3 Sell recommendations, according to market data. The consensus price target of $19.86 represents modest upside from current levels.
Sonelokimab is a novel nanobody targeting interleukin-17A and IL-17F, cytokines that play key roles in inflammatory pathways. The drug's dual-target mechanism and differentiated delivery platform have generated considerable interest among investors seeking exposure to next-generation immunotherapies.
The axSpA market represents a significant commercial opportunity, with current treatment options dominated by TNF inhibitors and IL-17 blockers including Novartis's Cosentyx and AbbVie's Humira. However, many patients fail to achieve adequate response or lose efficacy over time, creating substantial unmet medical need.
Institutional ownership stands at 81.3%, reflecting strong hedge fund and mutual fund interest in the company's prospects. The stock has recovered from a 52-week low of $5.95 but remains well below its June peak of $62.75, reflecting the volatility typical of clinical-stage biotech companies.
Investors will focus on management's commentary during the upcoming investor presentation regarding plans for Phase 3 development in axSpA, timing for additional pivotal studies, and potential partnership discussions. The disease modification signals from PET imaging could strengthen the company's position in negotiations with larger pharmaceutical companies seeking late-stage immunology assets.